<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1206">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05145452</url>
  </required_header>
  <id_info>
    <org_study_id>202003053</org_study_id>
    <nct_id>NCT05145452</nct_id>
  </id_info>
  <brief_title>n-3 Polyunsaturated Fatty Acids to Prevent and Treat Diabetic Neuropathy</brief_title>
  <acronym>NMF</acronym>
  <official_title>n-3 Polyunsaturated Fatty Acids to Prevent and Treat Diabetic Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sensorimotor neuropathy (SMN) and cardiovascular autonomic neuropathy (CAN) are the most&#xD;
      common complications of type 2 diabetes (T2D). SMN affects ~30% of people with T2D and CAN&#xD;
      ~20%. SMN causes pain, impairs and limits physical activity, and increases the risk for&#xD;
      physical disability, complications (such as foot ulcerations), and premature mortality.&#xD;
      Moreover, both motor and sensory nerve function are important regulators of muscle function;&#xD;
      impaired myofiber innervation causes myofiber loss, muscle fat infiltration, and increases&#xD;
      the risk of age-associated sarcopenia and falls. CAN often goes unrecognized because it&#xD;
      presents with non-specific symptoms, such as resting tachycardia and fixed heart rate,&#xD;
      exercise intolerance, and orthostatic hypotension. However, CAN is a serious problem because&#xD;
      it increases the risk for cardiovascular events and mortality several-fold. Both SMN and CAN&#xD;
      have long been considered a consequence of T2D, but it is now becoming clear that they&#xD;
      precede the diagnosis of T2D and are already detectable in people with prediabetes,&#xD;
      especially those with impaired glucose tolerance. Treatments for both SMN and CAN focus on&#xD;
      symptom management because there are no effective therapeutics that target the underlying&#xD;
      neuropathy. The results from studies conducted in animal models suggest fish oil-derived n-3&#xD;
      polyunsaturated fatty acids (n-3 PUFA) may have therapeutic effects for people with SMN and&#xD;
      CAN. The purpose of this proposal is to conduct a randomized controlled trial to test the&#xD;
      hypothesis that dietary supplementation with fish oil-derived n-3 PUFA improves sensorimotor&#xD;
      and cardiovascular autonomic functions in people with impaired glucose tolerance. Forty 55-80&#xD;
      year old men and women with impaired glucose tolerance (plasma glucose 2 h after a 75 g&#xD;
      glucose challenge ≥140 mg/dl) and evidence of SMN (assessed as epidermal nerve fiber density)&#xD;
      will be randomized to either receive fish oil-derived n-3 PUFA (4.2 g per day; n=20) or&#xD;
      placebo (n=20) for six months. Sensorimotor and cardiovascular autonomic function will be&#xD;
      evaluated after three and 6 months of the interventions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 14, 2021</start_date>
  <completion_date type="Anticipated">June 12, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 12, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>double-blind, randomized controlled trial in men and women</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Sensorimotor function</measure>
    <time_frame>Change from baseline to 6 months</time_frame>
    <description>Nerve conduction velocity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiovascular autonomic function</measure>
    <time_frame>Change from baseline to 6 months</time_frame>
    <description>Heart rate variability</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucose tolerance</measure>
    <time_frame>Change from baseline to 6 months</time_frame>
    <description>Glucose tolerance (plasma glucose concentration during a 75 gram glucose tolerance test)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>Change from baseline to 6 months</time_frame>
    <description>Oral insulin sensitivity index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beta cell function</measure>
    <time_frame>Change from baseline to 6 months</time_frame>
    <description>Insulin secretion rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma triglyceride concentration</measure>
    <time_frame>Change from baseline to 6 months</time_frame>
    <description>Plasma triglyceride concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle strength</measure>
    <time_frame>Change from baseline to 6 months</time_frame>
    <description>Muscle strength</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical performance</measure>
    <time_frame>Change from baseline to 6 months</time_frame>
    <description>Physical performance test</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Diabetic Neuropathies</condition>
  <arm_group>
    <arm_group_label>Intervention Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to n-3 PUFA will receive a total of 4.2 g/d of fish oil.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects randomized to placebo will receive 4.2 g/d sunflower oil.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects assigned to the control group will be tested once</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fish-oil derived n-3 polyunsaturated fatty acids</intervention_name>
    <description>4.2 g/d (7 pills with 600 mg each)</description>
    <arm_group_label>Intervention Group</arm_group_label>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age: ≥55 and ≤80 years&#xD;
&#xD;
          -  BMI: ≥25.0 and ≤39.9 kg/m2;&#xD;
&#xD;
          -  normal glucose tolerance (fasting plasma glucose &lt;100 mg/dl and plasma glucose 2 h&#xD;
             after a 75 g glucose challenge &lt;140 mg/d) (control group) or impaired glucose&#xD;
             tolerance (plasma glucose 2 h after a 75 g glucose challenge ≥140 mg/dl) (intervention&#xD;
             groups)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  age: &lt;55 and &gt;80 years&#xD;
&#xD;
          -  BMI: &lt;25.0 and &gt;39.9 kg/m2&#xD;
&#xD;
          -  plasma glucose 2 h after a 75 g glucose challenge &lt;140 mg/dl&#xD;
&#xD;
          -  treatment for T2D, except for metformin&#xD;
&#xD;
          -  regular structured high-intensity exercise &gt;150 min total per week&#xD;
&#xD;
          -  significant neurological or other organ system dysfunction (e.g., progressive&#xD;
             neuromuscular disease, unstable angina, vasculitis, certain cardiopulmonary diseases,&#xD;
             cancer that has been in remission for &lt;5 years, dementia, allergies to the dietary&#xD;
             supplement) or significant ambulatory impairments (e.g., limb amputations, being&#xD;
             wheelchair-bound)&#xD;
&#xD;
          -  use of certain medications that are incompatible with the study procedures (e.g.,&#xD;
             certain anticoagulants) or could confound the study outcomes (e.g., anabolic steroids,&#xD;
             metronidazole, etc) alcohol use disorder as defined by the NIAAA or use of controlled&#xD;
             substances or smoking &gt;20 cigarettes per week&#xD;
&#xD;
          -  regular consumption of fish oil supplements or &gt;2 servings of fatty fish per week&#xD;
&#xD;
          -  x) prisoners, and persons who are unable to grant voluntary informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bettina Mittendorfer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bettina Mittendorfer, Ph.D.</last_name>
    <phone>314-362-8450</phone>
    <email>mittend@wustl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brittney Mason</last_name>
      <email>brittneymason@wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bettina Mittendorfer, Ph.D.</last_name>
      <phone>314-362-8450</phone>
      <email>mittendb@wustl.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 9, 2020</study_first_submitted>
  <study_first_submitted_qc>November 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2021</study_first_posted>
  <last_update_submitted>November 22, 2021</last_update_submitted>
  <last_update_submitted_qc>November 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>Bettina Mittendorfer</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

